Researchers at Hefei Amvite Pharmaceutical Co. Ltd. reported the discovery and preclinical evaluation of a series of structurally modified ziritaxestat derivatives, leading to the identification of more potent autotaxin inhibitors.
Systemic sclerosis (SSc) is a particularly severe form of fibrotic disease that affects multiple organs. SSc is the most deadly autoimmune rheumatic disease.
BLR Bio LLC has announced new data on BLR-200, its lead compound for systemic sclerosis and lung fibrosis. In the new study, BLR-200 demonstrated the ability to reduce key disease tissue markers for fibrotic lung disease.
Certa Therapeutics Pty Ltd. has acquired Occurx Pty Ltd. in a move to strengthen its pipeline to target multiple fibrotic diseases as both companies share a focus on targeting GPR68, a defined G protein-coupled receptor (GPCR) receptor that mediates signaling pathways associated with inflammation and fibrosis and is thought to be a master switch of fibrosis.
Certa Therapeutics Pty Ltd. has acquired Occurx Pty Ltd. in a move to strengthen its pipeline to target multiple fibrotic diseases as both companies share a focus on targeting GPR68, a defined G protein-coupled receptor (GPCR) receptor that mediates signaling pathways associated with inflammation and fibrosis and is thought to be a master switch of fibrosis.
The FDA has awarded U.S. orphan drug designation to Eydisbio Inc.’s EYD-001 (formerly HS-276), a highly selective and potent, orally bioavailable TAK1 inhibitor for the treatment of systemic sclerosis. Eydisbio plans to initiate clinical trials in the near future.
Eydisbio Inc. has been awarded a $2.6 million phase II Small Business Innovation Research (SBIR) grant from the National Institute of Health’s (NIH) National Heart, Lung, and Blood Institute (NHLBI) to support its ongoing research into the efficacy of TAK1 inhibition in animal models of systemic sclerosis.
